Positive Results from IBI10103 Phase I Study with MagSense HER2 Imaging Agent
Posted: 12 December 2023 Imagion Biosystems Limited (ASX: IBX) today announces positive results following completion of the IBI10103 phase I clinical trial evaluating the safety and clinical feasibility of MagSense® HER2 Imaging Agent (MSH2IA) as an adjunct to MRI for…
BioNTech Partnership To Deliver Next Generation Cancer Care
Posted: 12 December 2023 Victoria’s standing as a leading producer of life-saving vaccines and medicines will grow with global giant BioNTech creating a research and manufacturing facility in Melbourne, in partnership with the Allan Labor Government. Building on…
The power of IFN-e: ovarian cancer breakthrough
Posted: 12 December 2023 In a significant breakthrough published in the top scientific journal, Nature Hudson Institute researchers have linked ovarian cancer to the absence of a naturally occurring protein in the female reproductive tract called interferon epsilon (IFN-e). The…
“Shared care” preferred by patients, cheaper, just as effective
Posted: 11 December 2023 A Peter Mac-led study has found sharing follow-up care between a GP and hospital-based specialists was preferred by bowel cancer patients, was cheaper for the healthcare system and was just as effective as standard…
Immutep Receives A$2.6 million R&D Tax Incentive from French Government
Posted: 11 December 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep“ or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce it has received a €1,595,475 (~…
Positive Topline Results from Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer Presented at SABCS
Posted: 11 December 2023 Telix announces positive topline results from the Phase II OPALESCENCE investigator-initiated trial (IIT) of its carbonic anhydrase IX (CAIX)-targeting positron emission tomography (PET) imaging candidate, TLX250-CDx (89Zr-DFO-girentuximab), in patients with triple negative breast cancer…
Game-Changing Research: Results from SVI’s BANDIT Type 1 Diabetes Trial
Posted: 11 December 2023 I am very proud to announce the results of our BANDIT trial – a world-first clinical trial investigating the use of an existing immunotherapy drug (baricitinib) to slow or stop the killing of insulin-producing…
Dedicated unit for CAR T and other cellular therapy patients opens at Peter Mac
Posted: 5 December 2023 A new dedicated treatment unit has opened at Peter Mac to care for patients receiving cell-based treatments, including CAR T-cell therapy. The unit, on Level 1 of Peter Mac’s main facility in Parkville, has…
2023 Neuren completes enrolment in Pitt Hopkins syndrome Phase 2 trial
Posted: 5 December 2023 Neuren Pharmaceuticals (ASX: NEU) today announced that enrolment of subjects into its Phase 2 clinical trial of NNZ-2591 in Pitt Hopkins syndrome has been completed. Top-line results from the trial are expected to be…
BioCurate Board Announces Kathy Nielsen PhD M.Pharm M. IP. Law RTTP GAICD as New CEO
Posted: 5 December 2023 BioCurate, the independently operated joint venture between the University of Melbourne and Monash University, announced today it has appointed Dr. Kathy Nielsen to the role of Chief Executive Officer. Dr. Nielsen brings over 25…
Approval to Initiate Phase2 Pancreatic Cancer Trial in Korea
Posted: 5 December 2023 Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce that the Korean Ministry of Food and Drug Safety (MFDS) have approved the clinical trial to test narmafotinib (AMP945) in combination…
Gene linked to persistent stuttering into adulthood uncovered
Posted: 1 December 2023 A new study led by University of Melbourne researchers has discovered a link between a new gene pathway and structural brain anomalies in some people who stutter into adulthood, opening up promising research avenues to…
